Virpax Pharmaceuticals, Inc. (VRPX)
OTCMKTS
· Delayed Price · Currency is USD
0.0210
0.00 (0.00%)
At close: Dec 5, 2025
Virpax Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | 1.51 | 9.14 | 19 | 36.84 | 0.05 | Upgrade
|
| Cash & Short-Term Investments | 1.51 | 9.14 | 19 | 36.84 | 0.05 | Upgrade
|
| Cash Growth | -83.45% | -51.88% | -48.44% | 67134.82% | 31.92% | Upgrade
|
| Prepaid Expenses | 0.04 | 0.2 | 0.18 | 0.16 | 0.01 | Upgrade
|
| Other Current Assets | 0 | 0.28 | 0.5 | 2.57 | 0 | Upgrade
|
| Total Current Assets | 1.56 | 9.63 | 19.67 | 39.57 | 0.07 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.39 | Upgrade
|
| Total Assets | 1.56 | 9.63 | 19.67 | 39.57 | 0.47 | Upgrade
|
| Accounts Payable | 0.04 | 0.02 | 0.04 | 0.02 | 0.02 | Upgrade
|
| Accrued Expenses | 2.43 | 1.68 | 1.06 | 2.07 | 3.08 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 0.54 | Upgrade
|
| Current Income Taxes Payable | - | - | - | - | 0.01 | Upgrade
|
| Other Current Liabilities | - | 6 | 2 | - | - | Upgrade
|
| Total Current Liabilities | 2.47 | 7.69 | 3.09 | 2.09 | 3.66 | Upgrade
|
| Long-Term Debt | - | - | - | - | 1.02 | Upgrade
|
| Total Liabilities | 2.47 | 7.69 | 3.09 | 2.09 | 4.68 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 70.7 | 61.48 | 60.93 | 60.19 | 6.43 | Upgrade
|
| Retained Earnings | -71.61 | -59.54 | -44.35 | -22.7 | -10.65 | Upgrade
|
| Shareholders' Equity | -0.91 | 1.93 | 16.58 | 37.48 | -4.22 | Upgrade
|
| Total Liabilities & Equity | 1.56 | 9.63 | 19.67 | 39.57 | 0.47 | Upgrade
|
| Total Debt | - | - | - | - | 1.57 | Upgrade
|
| Net Cash (Debt) | 1.51 | 9.14 | 19 | 36.84 | -1.51 | Upgrade
|
| Net Cash Growth | -83.45% | -51.88% | -48.44% | - | - | Upgrade
|
| Net Cash Per Share | 8.89 | 195.13 | 405.53 | 1379.38 | -121.54 | Upgrade
|
| Filing Date Shares Outstanding | 1.06 | 0.05 | 0.05 | 0.05 | 0.02 | Upgrade
|
| Total Common Shares Outstanding | 0.6 | 0.05 | 0.05 | 0.05 | 0.01 | Upgrade
|
| Working Capital | -0.91 | 1.93 | 16.58 | 37.48 | -3.59 | Upgrade
|
| Book Value Per Share | -1.53 | 41.29 | 353.82 | 799.93 | -335.12 | Upgrade
|
| Tangible Book Value | -0.91 | 1.93 | 16.58 | 37.48 | -4.22 | Upgrade
|
| Tangible Book Value Per Share | -1.53 | 41.29 | 353.82 | 799.93 | -335.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.